In a report released yesterday, Vik Chopra from Wells Fargo maintained a Buy rating on NeuroPace (NPCE – Research Report), with a price target of $17.00.
Vik Chopra has given his Buy rating due to a combination of factors that highlight NeuroPace’s strong financial performance and promising future prospects. The company’s Q4 revenue reached the upper limit of the pre-announced range, surpassing consensus expectations, which demonstrates robust sales momentum. Additionally, the management’s decision to maintain their 2025 guidance for sales, gross margin, and operating expenses reflects confidence in their strategic direction.
Moreover, NeuroPace’s successful equity raise, which generated approximately $69.8 million, strengthens its financial position and supports future growth initiatives. The ongoing NAUTILUS trial, expected to complete its one-year follow-up soon, is seen as a potential growth catalyst, with FDA submission anticipated in the second half of 2025. These factors, combined with the company’s efforts to expand its prescriber base and increase direct-to-consumer campaign returns, contribute to the positive outlook and justify the Buy rating.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $20.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NPCE in relation to earlier this year.